Medication
Omvoh
DIN 02559242 · Eli Lilly Canada Inc
What it is
- Active ingredients
- Mirikizumab — 100 mg
- Mirikizumab — 200 mg
- Form and route
- Kit · Subcutaneous
- Schedule
- SCHEDULE D, PRESCRIPTION
- Authorised since
- 2025-10-22
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.
How it is classified
- Anatomical main group
- Antineoplastic and immunomodulating agents
- ATC code
- L04AC24
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of L04AC24, see the WHO ATC/DDD Index.
Recalls and safety alerts
Recall matching is not available yet.
RxMonitor does not yet match Health Canada recalls to individual products — that arrives in a later release. Nothing on this page should be read as confirming that this medication has not been recalled.